OA12554A - Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders. - Google Patents
Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders. Download PDFInfo
- Publication number
- OA12554A OA12554A OA1200300213A OA1200300213A OA12554A OA 12554 A OA12554 A OA 12554A OA 1200300213 A OA1200300213 A OA 1200300213A OA 1200300213 A OA1200300213 A OA 1200300213A OA 12554 A OA12554 A OA 12554A
- Authority
- OA
- OAPI
- Prior art keywords
- triene
- methano
- hexahydro
- pyrido
- oxo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27256601P | 2001-03-01 | 2001-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA12554A true OA12554A (en) | 2006-06-07 |
Family
ID=23040351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200300213A OA12554A (en) | 2001-03-01 | 2002-02-20 | Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders. |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20020193360A1 (hu) |
| EP (1) | EP1363606A1 (hu) |
| JP (1) | JP2004527500A (hu) |
| KR (1) | KR20030076717A (hu) |
| CN (1) | CN1494422A (hu) |
| AP (1) | AP2002002465A0 (hu) |
| AR (1) | AR033425A1 (hu) |
| BG (1) | BG108131A (hu) |
| BR (1) | BR0207802A (hu) |
| CA (1) | CA2439581A1 (hu) |
| CR (1) | CR7059A (hu) |
| CZ (1) | CZ20032338A3 (hu) |
| DO (1) | DOP2002000345A (hu) |
| EA (1) | EA200300854A1 (hu) |
| EC (1) | ECSP034759A (hu) |
| EE (1) | EE200300422A (hu) |
| GT (1) | GT200200039A (hu) |
| HU (1) | HUP0303448A3 (hu) |
| IL (1) | IL157465A0 (hu) |
| IS (1) | IS6905A (hu) |
| MA (1) | MA26999A1 (hu) |
| MX (1) | MXPA03007834A (hu) |
| NO (1) | NO20033821L (hu) |
| NZ (1) | NZ527397A (hu) |
| OA (1) | OA12554A (hu) |
| PA (1) | PA8540701A1 (hu) |
| PE (1) | PE20020927A1 (hu) |
| PL (1) | PL364081A1 (hu) |
| SK (1) | SK10752003A3 (hu) |
| TN (1) | TNSN02018A1 (hu) |
| UY (1) | UY27188A1 (hu) |
| WO (1) | WO2002069948A1 (hu) |
| ZA (1) | ZA200306193B (hu) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080004332A1 (en) * | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| US20050065205A1 (en) * | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US8030300B2 (en) | 2003-06-10 | 2011-10-04 | Georgetown University | Ligands for nicotinic acetylcholine receptors, and methods of making and using them |
| TW201207390A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Method for screening agent for antidepressant activity |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| EP1924712B1 (en) * | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| WO2007139818A2 (en) | 2006-05-22 | 2007-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmacological treatment of cognitive impairment |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| AU2013202426B2 (en) * | 2006-10-16 | 2015-08-06 | Bionomics Limited | Novel anxiolytic compounds |
| EP2540722B1 (en) * | 2006-10-16 | 2016-06-08 | Bionomics Limited | Novel anxiolytic compounds |
| CA2873179A1 (en) | 2007-02-09 | 2008-08-21 | Blanchette Rockefeller Neurosciences Institute | Use of bryostatins and neristatins in the treatment of cognitive impairment due to head trauma |
| WO2009143347A2 (en) * | 2008-05-22 | 2009-11-26 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
| WO2009155403A2 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of varenicline and intermediates thereof |
| US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
| US10206921B2 (en) * | 2009-06-03 | 2019-02-19 | The Regents Of The University Of California | Methods and compositions for treating a subject for central nervous system (CNS) injury |
| RU2012102052A (ru) * | 2009-06-22 | 2013-11-20 | Тева Фармасьютикал Индастриз Лтд. | Твердые формы солей варениклина и способы их получения |
| NO3034079T3 (hu) | 2010-11-15 | 2018-06-09 | ||
| JP2014510065A (ja) | 2011-03-02 | 2014-04-24 | バイオノミックス リミテッド | 治療薬としての新規な小分子 |
| US20140051701A1 (en) * | 2011-03-02 | 2014-02-20 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
| US9133188B2 (en) | 2011-05-12 | 2015-09-15 | Bionomics Limited | Methods for preparing naphthyridines |
| NZ722077A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| AU2016279052A1 (en) | 2015-06-19 | 2018-02-15 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN112601749B (zh) | 2018-06-19 | 2024-03-26 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 |
| CN116008442B (zh) * | 2023-03-27 | 2023-06-30 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的合成中间体的杂质检测方法 |
| CN116077459B (zh) * | 2023-04-10 | 2023-07-07 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的胶囊剂及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010023313A (ko) * | 1997-08-25 | 2001-03-26 | 해피 페너 ; 해리 에이치. 페너 2세 | Ｇａｂａ 뇌 수용체 리간드로서의 치환된4-옥소-나프티리딘-3-카르복스아미드 |
| WO2000071528A1 (en) * | 1999-05-25 | 2000-11-30 | Neurogen Corporation | 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands |
-
2002
- 2002-02-20 SK SK1075-2003A patent/SK10752003A3/sk not_active Application Discontinuation
- 2002-02-20 IL IL15746502A patent/IL157465A0/xx unknown
- 2002-02-20 CN CNA028058046A patent/CN1494422A/zh active Pending
- 2002-02-20 CA CA002439581A patent/CA2439581A1/en not_active Abandoned
- 2002-02-20 OA OA1200300213A patent/OA12554A/en unknown
- 2002-02-20 WO PCT/IB2002/000515 patent/WO2002069948A1/en not_active Application Discontinuation
- 2002-02-20 EA EA200300854A patent/EA200300854A1/ru unknown
- 2002-02-20 MX MXPA03007834A patent/MXPA03007834A/es unknown
- 2002-02-20 EP EP02700509A patent/EP1363606A1/en not_active Withdrawn
- 2002-02-20 EE EEP200300422A patent/EE200300422A/xx unknown
- 2002-02-20 NZ NZ527397A patent/NZ527397A/en unknown
- 2002-02-20 KR KR10-2003-7011366A patent/KR20030076717A/ko not_active Application Discontinuation
- 2002-02-20 PL PL02364081A patent/PL364081A1/xx not_active Application Discontinuation
- 2002-02-20 CZ CZ20032338A patent/CZ20032338A3/cs unknown
- 2002-02-20 HU HU0303448A patent/HUP0303448A3/hu unknown
- 2002-02-20 JP JP2002569125A patent/JP2004527500A/ja active Pending
- 2002-02-20 BR BR0207802-3A patent/BR0207802A/pt not_active IP Right Cessation
- 2002-02-26 DO DO2002000345A patent/DOP2002000345A/es unknown
- 2002-02-26 PE PE2002000157A patent/PE20020927A1/es not_active Application Discontinuation
- 2002-02-26 US US10/083,743 patent/US20020193360A1/en not_active Abandoned
- 2002-02-27 UY UY27188A patent/UY27188A1/es not_active Application Discontinuation
- 2002-02-27 GT GT200200039A patent/GT200200039A/es unknown
- 2002-02-27 AR ARP020100693A patent/AR033425A1/es not_active Application Discontinuation
- 2002-02-28 PA PA20028540701A patent/PA8540701A1/es unknown
- 2002-02-28 TN TNTNSN02018A patent/TNSN02018A1/fr unknown
- 2002-02-28 AP APAP/P/2002/002465A patent/AP2002002465A0/en unknown
-
2003
- 2003-08-07 IS IS6905A patent/IS6905A/is unknown
- 2003-08-11 ZA ZA200306193A patent/ZA200306193B/en unknown
- 2003-08-19 MA MA27286A patent/MA26999A1/fr unknown
- 2003-08-25 CR CR7059A patent/CR7059A/es not_active Application Discontinuation
- 2003-08-25 BG BG108131A patent/BG108131A/xx unknown
- 2003-08-28 NO NO20033821A patent/NO20033821L/no not_active Application Discontinuation
- 2003-09-01 EC EC2003004759A patent/ECSP034759A/es unknown
- 2003-12-02 US US10/727,934 patent/US20040082555A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA12554A (en) | Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders. | |
| EP1272218B1 (en) | A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines | |
| JP5666910B2 (ja) | 認知機能障害を治療するためのキット、組成物、製品もしくは医薬 | |
| US20070225316A1 (en) | Methods and compositions for treating schizophrenia | |
| JP2004511512A (ja) | 認識障害の治療のためのアセチルコリンエステラーゼ阻害薬およびｇａｂａａ反作用薬の組合せ使用 | |
| WO2008013556A1 (en) | Combination 5-ht7 receptor antagonist and serotonin reuptake inhibitor therapy | |
| JP6675688B2 (ja) | ５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法 | |
| MXPA02011051A (es) | Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero. | |
| US20040220184A1 (en) | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) | |
| JP6433482B2 (ja) | 認知機能を改善するための方法および組成物 | |
| JP2023534189A (ja) | Ｇａｂａａアルファ５アゴニストおよびｓｖ２ａ阻害剤の組合せ物ならびに認知障害の処置において使用する方法 | |
| KR20010050225A (ko) | 포유동물에서의 니코틴 탐닉의 예방 및 치료를 위한 약학조성물 | |
| US9023788B2 (en) | Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders | |
| KR20230096003A (ko) | 만성 ssri 레지멘 후 실로시빈에 대한 민감도를 증가시키기 위한 벤조디아제핀의 사용 | |
| CZ2004524A3 (cs) | Agonisté nikotinového acetylcholinového receptoru v léčbě syndromu neklidných nohou | |
| AU2022328217A1 (en) | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same | |
| Butini et al. | Novel antipsychotic agents: recent advances in the drug treatment of schizophrenia | |
| AU2002233585A1 (en) | Use of GABAA inverse agonists in combination with nicotine receptor partial agonisits, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders | |
| US20140107087A1 (en) | Methods, Compounds and Pharmaceutical Compositions for Treating Anxiety and Mood Disorders | |
| RU2508096C2 (ru) | Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии |